An investigation for investors in BioScrip Inc (NASDAQ:BIOS) shares over potential securities laws violations by BioScrip was announced and NASDAQ:BIOS stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 06/02/2015 -- A Federal Judge decided that a lawsuit against BioScrip over alleged Securities Laws Violations will partially move forward. Additionally, an investigation for investors who purchased shares of BioScrip Inc (NASDAQ:BIOS) in 2012 or earlier and currently hold any of those NASDAQ:BIO shares, was announced concerning potential breaches of fiduciary duties by certain BioScrip officers and directors.
Investors who purchased shares of BioScrip Inc (NASDAQ:BIOS) in 2012 or earlier and currently hold any of those shares, have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of BioScrip Inc (NASDAQ:BIOS) concerning whether a series of statements by BioScrip regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On September 23, 2013, BioScrip Inc disclosed that the Company received a civil investigative demand issued by the United States Attorney's Office for the Southern District of New York and a subpoena from the New York State Attorney General's Medicaid Fraud Control Unit, regarding the distribution of the Novartis Pharmaceuticals Corporation product Exjade(R) by the Company's legacy specialty pharmacy division.
On September 30, 2013, a lawsuit was filed against BioScrip over alleged Securities Laws Violations. The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that BioScrip Inc improperly distributed the product Exjade through its specialty pharmacy operations, that BioScrip Inc was in violation of certain federal and state laws and regulations, and that as a result of the foregoing BioScrip's statements were materially false and misleading at all relevant times.
On January 8, 2014 U.S. Department of Justice disclosed that BioScrip agreed to forfeit $15 million for the Company's alleged participation in an alleged kickback scheme with Novartis Pharmaceuticals Corporation related to Novartis's product Exjade.
On March 31, 2015, a federal judge denied, in part, a motion to dismiss the lawsuit was filed on September 30, 2013 against BioScrip over alleged Securities Laws Violations.
Those who purchased shares of BioScrip Inc (NASDAQ:BIOS) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego